https://www.selleckchem.com/products/AZD0530.html
In 2017, all people with severe hemophilia B in Ireland switched to recombinant factor IX Fc fusion protein concentrate (rFIXFc) prophylaxis. Patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are important to evaluate with new treatments. To assess HRQoL in people with severe hemophilia B and their experience after switching to rFIXFc prophylaxis. Participants completed a Patient Reported Outcomes Burden and Experience (PROBE) questionnaire on initiation and following two years of rFIXFc prophylaxis. The PROBE
Like
Comment
Share
